The collaboration will study genetic testing and the impact of genetics on the efficacy of prescription drugs.
Pharmacy benefit manager Medco Health Solutions Inc. and the Food and Drug Administration (FDA) have entered into a research partnership to study genetic testing and the impact of genetics on the efficacy of prescription drugs.
Medco and the FDA will jointly develop research projects, programs and strategies in the area of pharmacogenomics, collectively aimed at improving patient health and quality in the delivery of care.
"An increasing number of drugs are including genetic information in their labels and we're finding out how genes affect some drugs that have been widely used for generations," Medco Chief Medical Officer Dr. Robert Epstein said in a company statement. "Studying this field can advance pharmacy care to remove some of the trial and error in how medications are prescribed."